Exploring FDA's Orange, Green And Purple Books And Pharmaceutical Patent Strategies

Author: LawSphereX

Category: Intellectual Property

Published: 2026-08-23T19:46:50.661Z

Updated: 2026-08-30T07:11:01.596Z

EXPLORING FDA'S ORANGE, GREEN AND PURPLE

BOOKS AND PHARMACEUTICAL PATENT STRATEGIES

Anuska Mahto, BBA-LLB (Hons.), ICFAI Law School, Hyderabad

ABSTRACT

The report aims at assessing, in real detailed form, the regulatory frameworks which oversee the approval and listing of the biological products and generic drugs in the United States with a specific focus on the Purple Book, Orange Book, Green Book and Pharmaceutical patents. It clearly explains the different roles and contents of those compendiums, outlines processes involved in submitting an Abbreviated New Drug Application and explains the implications of patent listings and their extensions under current legislation. This would therefore offer an all-round understanding of these regulatory resources for all stakeholders within the pharmaceuticals industry.

This report will also include procedure involved in patent listing and will finally conclude by mentioning the further extension period for patents1 under the legislation Keywords: Orange Book, Pharmaceutical Patents, Purple Book, Green Book, FDA, Hatch-Waxman Act, ANDA process. 1 A patent is a legal document that guarantees an inventor the sole right to market their invention for a certain amount of time.

INTRODUCTION

The Food and Drug Administration (hereinafter referred to as ‘FDA’) is the agency which was enacted by the United States Federal Food, Drug and Cosmetic Act2 (hereinafter referred to as ‘FD&C Act’). The said Act is a set of laws passed by the United States Congress in the year

1938. The FDA plays a crucial role in safeguarding public health by ensuring that human and

veterinary medications, biological products, and medical devices are safe, effective, and reliable; and it also guarantees the safety of the country's food supply, cosmetics, and items that produce radiation. The Hatch-Waxman Act3 aims to strike a balance between fostering innovation and ensuring public access to affordable medications. It provides pharmaceutical patent holders with specific exclusive rights, including extended patent terms and the option to postpone FDA approval of generic medications for up to 30 months while patent disputes are resolved. This functions as an automatic preliminary injunction throughout the litigation phase. The FDA plays a crucial role in promoting public health by accelerating innovations that enhance the effectiveness, safety, and affordability of medical products.

It also guarantees that the public receives accurate, science-based information to properly utilize medical products and food for sustaining and enhancing health. 4 The FDA is also responsible with supervising the production, promotion, and distribution of tobacco products to protect public health and decrease tobacco consumption among minors. It also plays a critical role in the Nation's capacity to counterterrorism by not only maintaining its ongoing efforts to ensure the security of the food supply, but also by promoting the growth of medical products to address both deliberate and naturally occurring public health threats. 5 Hereinafter we will discuss in detail about the Purple Book, Green Book, Orange Book, the ANDA process and about the Pharmaceutical Patents.

2 The federal law that gives the FDA authority to oversee the safety of food, drugs, and cosmetics.

3 The Drug Price Competition and Patent Term Restoration Act is referred as The Hatch-Waxman Act.

4 Chandan Saini, Ashish Miglani, Pankaj Musyuni, Geeta Aggarwal. "Review of form 483s and warning letters to pharmaceutical manufacturers issued by USFDA", Journal of Generic Medicines: The Business Journal for the Generic Medicines Sector, 2021

5 What we do |FDA https://www.fda.gov/about-fda/what-we-do

THE HATCH-WAXMAN ACT6 The Drug Price Competition and Patent Term Restoration Act (known as The Hatch-Waxman Act) was passed by the Congress in 1984 to regulate the drug approvals in the United States. The Hatch- Waxman Act amended the Food, Drug and Cosmetic Act, 1938 (the FD&C Act) by introducing processes that simplifies the approval procedure for generic drugs along with safeguarding the incentives. The said Act also added provisions which required the applicants to submit patents to Food, Drug Administration to claim for the drug itself or the method of using the drug. Such patents get listed in the authorised publication “Approved Drug Products with Therapeutic Equivalence Evaluations”, commonly known as the Orange Book.

It developed a structured patent litigation system with a transparent procedure and set timeline, enabling generic manufacturers to challenge the patents of brand manufacturers in federal court without facing the risk of patent infringement liability. For over thirty years, the Hatch- Waxman Act has supported innovation, encouraged market competition, and maintained the United States' position as a global leader in biopharmaceutical research and development. Since the passage of the Hatch-Waxman Act, the generic pharmaceutical industry has experienced significant expansion, while biopharmaceutical companies have continued to create and develop groundbreaking treatments for complex and expensive diseases. This legislation enables the United States to uphold its leadership in medical innovation by striking a balance between affordability, innovation, and market competition.

PURPLE BOOK7 The Purple Book is formally referred to as "Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Inter-changeability Evaluations" under the Public Health Service Act8 (referred to as the PHS Act). The PHS Act contains a list of these biological products inclusive of biosimilar and interchangeable biological products that are permitted or licensed by the FDA. The regulation of the biological products falls under the Section 351 of the PHS Act. Such biological products are also classified as either drugs or medical devices under the Food, Drug and Cosmetics Act (the FD&C Act). Two tentative lists—that is, one of the biologics approved by the CDER9 and another by the CBER—are

6 WHAT IS HATCH-WAXMAN? https://www.phrma.org/-/media/Project/PhRMA/PhRMA-Org/PhRMA-

Org/PDF/D-F/Fact-Sheet_What-is-Hatch-Waxman_June-2018.pdf

7 What Are Purple and Orange Books? https://www.freyrsolutions.com/what-are-purple-and-orange-books

8 The U.S. law that governs public health, including the approval of biological products.

9 The FDA Center responsible for the regulation of drugs.

given in this book. Some additional information is also included. Additional details related to the biologics in this book are: • Biologics License Application (BLA)10 Number • Proprietary Product Names • Non-proprietary Product Names • Date when the Product was authorised in the Market. • Date of First Licensure • Whether Product is Biosimilar or Interchangeable • Reference Product with Expiry Date • Whether the Product is withdrawn from the Market. a. PURPOSE Purpose of the Purple Book: • To aid the user in ascertaining if the biological product has received FDA authorization under the PHS Act for a reference product that is already approved as a biological product. • To assist in determining whether there is any exclusivity with the provided reference product. b.

REFERENCE PRODUCT As that term is used in section 351(i)(4), a "reference product" is the single biological product licensed by the FDA under section 351(a) of the PHS Act to which a proposed biological product is compared in an application submitted under section 351(k). 11

10 An application for the approval of a biological product.

11 See Section 351 (i)(4) and 351 (a) of the Public Health Service Act

c. BIOSIMILAR As defined by section 351(i)(2), "biosimilar" or "biosimilarity" refers to a biological product's high degree of similarity to the reference product, even in the case of slight variations in clinically inactive component composition, and the absence of clinically significant variations in the biological product's potency, safety, or purity. d. INTERCHANGEABLE BIOLOGICAL PRODUCT A product licenced under section 351(k) that is proven to be biosimilar to the reference product and demonstrated to produce the same clinical outcome in any patient is considered as an "interchangeable" biological product under section 351(k)(4). e. BIOLOGICAL PRODUCT PATENT TRANSPARENCY Amendments to 42 U.S.C. 262(k) of the Biologics Price Competition and Innovation Act, relating to the Biological Product Patent Transparency (BPPT), were effective on June 25,

2021. The BPPT section requires that, not later than 180 days of its enactment, FDA must

publish and make accessible to the public, in a searchable, electronic format, a list of biological products, by non-proprietary name, for which a biologics license under Sect. 351(a) or 351(k) of the PHS Act is in effect. These amendments would require publication of the FDA’s "Purple Book," provide that the said book contains additional information, such as patent lists submitted by a reference product sponsor (RPS) to a biosimilar applicant under 42 U. S. C. 262(l)(3)(A) or (l)(7), and require the FDA to update the Purple Book every 30 days. THE GREEN BOOK12 The Green Book is a compilation of all highly rated FDA approved and conditionally approved animal drugs. It contained not only listing data, but also patent inclusivity.

The material in the Green Book is not only utilized by drug firms interested preparing copies of animal drugs approved exclusively for members of species and marketed by ANADAs13, but it also serves as a resource to the public. Medications for animals that are indexed will not be listed in the 12 Animal Drugs @ FDA Explained https://www. fda. gov/animal-veterinary/approved-animal-drug-productsgreen-book/animal-drugs-fda-explained

13 Abbreviated New Animal Drug Applications (ANADAs) for approved generic animal drugs

Green Book such as if a drug is not found in the Green Book, then it is not approved by FDA. THE ORANGE BOOK The Orange Book, also known as "Approved Drug Products with Therapeutic Equivalence Evaluations," is a very crucial document that includes the lists of FDA-approved drugs based on safety and efficacy under the Federal Food, Drug, and Cosmetic Act. Excluded in the list are drugs not approved for being safe or effective, while including those subjected to regulatory actions. An electronic version of the Orange Book, updated daily since 2005, helps the health professionals and public locate less-costly generic drug equivalents. The Orange Book is divided into four parts: i. Approved prescription drug products with therapeutic equivalence evaluations ii.

Approved over-the-counter drug products for which NDAs or ANDAs are required because they are subject to a specific section of the FD&C Act iii. The drug products approved under Section 505 of the FD&C Act; covered by CBER14. iv. A cumulative list of all the different approved products; this includes products never marketed, those intended for export or discontinued without any safety or effectiveness concerns. 15 ABBREVIATED NEW DRUG APPLICATION (ANDA)16 To encourage generics for the listed drugs, the Hatch-Waxman Act put in place a fast-track approval process—an Abbreviated New Drug Application, or ANDA as mentioned in 21 U. S. C. § 355(j). There is no duty on the part of the company’s manufacturing generics to repeat clinical trials to prove safety and effectiveness, but the companies may rely upon the research conducted by the pioneer pharmaceutical companies as mentioned in 21 U. S.

C. § 355(j)(2)(A)(iv), (j)(8)(B). However, for the many years of research by pioneer pharmaceutical companies in establishing safety and effectiveness to be relied upon, an applicant filing an

14 The FDA Center responsible for the regulation of biological products.

15 Orange Book Preface, https://www.fda.gov/drugs/development-approval-process-drugs/orange-book-preface - :~:text=The%20Orange%20Book%20is%20composed,drug%20products%20with%20approval%20under 16 An application submitted to the FDA for the approval of a generic drug, demonstrating its bioequivalence to an already approved brand-name drug.

ANDA is required to demonstrate the bioequivalence of its generic drug with that of the NDA drug. The ANDA review process is comprised of the following: i. Pre-ANDA preparation: o Compilation of detailed data on the RLD17, including its complete chemical composition, pharmacological properties, formulation, labeling, and regulatory history. o Ensuring that the proposed generic drug is equivalent to the RLD. ii. ANDA preparation: o Contain an ANDA start with facts demonstrating the generic drug to be similar in terms of chemistry, pharmacology, and clinic performance to the RLD. iii. ANDA Submission o For this purpose, the filled ANDA is submitted, electronically, to the FDA's Center for Drug Evaluation and Research, CDER, through the FDA's electronic submissions gateway. iv. FDA Review: o The FDA reviews the ANDA to determine whether it meets the regulatory requirements for approval.

The phase may, in some cases, take about 30 months but can be accelerated in the case of drugs that deal with severe conditions or unmet medical needs. v. FDA decision: o After review, the FDA will either approve or refuse the ANDA. If approved, the

17 A previously approved drug product to which a new generic version is compared to show that it is

bioequivalent. permit allows the sponsor to market the generic drug. PHARMACEUTICAL PATENTS Pharmaceutical patents are important18. There are certain types of pharmaceutical patents that find a place in the Orange Book. The company filing their new drug application must include any patent that either: (1) claims the drug and is either a drug substance patent or a drug product patent; or (2) asserts a way of using the medication for which authorization is sought. If the drug is approved, this patent information in the NDA is then listed in the Orange Book along with the drug. An abbreviated new drug application (ANDA) contains data that, when submitted to the FDA, facilitates the review and subsequent approval of a generic drug product. A generic is an exact replica of a medication that has already received approval and been put on the market.

The term "abbreviated new drug applications" refers to the fact that they lack preclinical and clinical evidence from human and animal research that would prove their efficacy and safety. In contrast, a generic drug applicant must demonstrate scientifically that their product is bioequivalent, meaning it will function similarly to the original medication. Once authorised, the applicant can produce and sell the generic medication to offer the public a low-cost, safe, and efficient substitute for the branded, or original, version. PROCEDURE REGARDING PATENT LISTING

A patent listed in the Orange Book will let the NDA filer make use of several regulatory benefits under the Hatch-Waxman Act. It includes preventing FDA approval in case of potentially infringing products for generic manufacturers. In addition, any patent that covers a medicine listed in the Orange Book that is listed by the ANDA applicant must be certified as follows:

I.

No such patent information has been submitted to the FDA. II.

The patent has ceased to have legal effect. III.

The patent will cease to have legal effect on a specific date and therefore the 18 “Pharmaceutical patents” is defined as patents directed towards small molecules which are listed in the Orange Book. approval of the ANDA should be postponed until such date or IV.

The applicant for the above-mentioned drug under section 355(j)(2)(A)(vii) believes that the patent is invalid or will not be infringed during the manufacture, use or sale of the generic drug. • These options are referred to as Paragraph I, II, III, and IV Certifications, respectively. The type of certification contained in the ANDA links to the timing of ANDA approval. • Approval timing, in the case of Paragraph IV ANDAs, relies on two events: o First, whether within 45 days the pioneer drug company brings an infringement action upon learning that an ANDA has been filed containing a paragraph IV certification, and o Second, whether the company seeking approval was the first one to file an ANDA containing the so-called Paragraph IV Certification to a listed patent.

• The ANDA applicant are required to notify both the patentee and NDA holder regarding the factual and legal bases for the Paragraph IV Certification as outlined in 21 U. S. C. § 355(j)(2)(B). • After receiving such notice, the patentee and NDA holder can choose to file a lawsuit concerning all, some, or none of the patents referenced in the Paragraph IV Certification. • If within 45 days of receipt of notice, the patentee or NDA holder does not bring suit, the FDA may give final approval of the ANDA when the ANDA approval requirements are met. Conversely, if the brand name company sues within 45 days, then the FDA is not permitted to approve the ANDA for 30 months. • However, A court has the jurisdiction to extend or reduce the term of a 30-month stay on a condition that if either party in the lawsuit fails to reasonably cooperate in expediting the litigation.

As in the case of Eli Lilly & Co. v. Teva Pharms19 whereby the

19 557 F.3d 1346 (Fed. Cir. 2009)

defendant changed its ANDA close to the discovery date to refute the infringement claims and withheld its intention to change for eight months, thereby extending the stay. • 21 U. S. C. § 355(j)(5)(B)(iii)20 states that the FDA may then authorise the ANDA, or earlier if a court has held the patent(s)-in-suit are invalid or not infringed. The Patent is removed from the Orange Book when it expires. 21 PATENT TERM ADJUSTMENT The maximum term available for extension is five years if this term extension does not create a remaining patent term total of more than fourteen years. This 14-year period is referenced from the registration date of the drug product until the end date of the patent with the addition of the term extension. Any term extension under the legislation is effective from the patent's initial expiration date, including any Patent Term Adjustment.

Also, an additional requirement that will make a patent eligible for extension is that it needs to contain at least one claim covering the approved drug product, or its approved method of use or method of manufacture, and the following five conditions should be met: i. The patent is still in effect. ii. The term of the patent has never been extended. iii. The patent owner or his/her agent submits a complete and timely application for extension. iv. Before the product was used or marketed commercially, it underwent a period of regulatory assessment. The current law is based on the Supreme Court's 1964 decision in Brulotte v. Thys22. Brulotte held that post-expiration patent licencing is a per se misuse of the patents.

Brulotte has been avoided by crafty licensors who now bundle patented and unpatented licensing into the same agreement, so that a license does not rest on the life of an underlying

20 FEDERAL FOOD, DRUG, AND COSMETIC ACT, 1938

21 212 LEON SHARGEL & ISADORE KANFER, GENERIC DRUG PRODUCT DEVELOPMENT (Second ed. 2024).

22 379 U.S.307 (Brulloite)

patent alone. For example, trade secrets, technical data, copyrights, trademarks, and other values could be added in the license with a patent. But the license terms need to change with the expiration of the patent:

CONCLUSION

Given the foregoing, it is apparent that the regulatory framework for pharmaceutical and biological products (by reference to FDA rules under FD&C Act) while also addressing outdated Federal Food, Drug, and Cosmetic Act, 1938 (FFDCA) standards through a combination of statutes provisions within PHS Act as well has established an extensive system which leads equilibrium between interests in innovation towards public health and accessibility. Regulatory methods and releases such as the Purple Book, Green Book, Orange Book play a vital role in promoting transparency, competition among generic drug companies by delivering detailed product information for any approved products along with their bioequivalents/ generic versions through visibility of patent statuses.

The Abbreviated New Drug Application (ANDA) process, as outlined, serves to facilitate the introduction of generic pharmacological products into the marketplace, thereby augmenting consumer access to a wider array of cost-effective medicinal options in lieu of those supplied by original drug manufacturers, whilst simultaneously upholding the sanctity of their intellectual property rights. Additionally, it is imperative to contemplate the existence of alternative legal frameworks that establish distinctive incentives alongside simultaneous disincentives, such as adjustments in patent durations intended to extend exclusive rights.

Furthermore, one must factor in the regulatory provisions pertaining to pharmaceutical patents, exemplified by the Hatch-Waxman Act, which aims to strike a dual purpose: fostering innovation whilst simultaneously enabling the expeditious market entry of generic drugs. The interplay between the mechanisms of patent safeguarding and the approval processes instituted by the FDA plays a pivotal role in moulding a pharmaceutical environment that not only nurtures innovative endeavours but also furnishes patients with the motivation to secure access to crucial therapeutics that can prove lifesaving.

Considering the convoluted nature of the regulatory environment, it is crucial for various entities such as pharmaceutical corporations, healthcare professionals, and legal experts to consistently exercise caution in manoeuvrings through these frameworks to uphold compliance and maximize the advantageous outcomes of the regulatory mechanisms in promoting public health goals. The ongoing revisions and alterations to these regulations signify the changing characteristics of the pharmaceutical sector and highlight the FDA’s ongoing dedication to striking a balance between safeguarding public health and fostering innovation.

The comprehensive evaluation reconfirms the essential function of the FDA concerning the oversight of pharmaceutical entities and highlights the necessity for comprehending the complex legal and regulatory structures that dictate the progression, sanctioning, and dissemination of pharmaceutical commodities within the jurisdiction of the United States.

REFERENCES

1. United States Federal Food, Drug, and Cosmetic Act, 1938

2. The Drug Price Competition and Patent Term Restoration Act, 1984

3. Federal Food, Drug and Cosmetic Act, 1938 https://uscode.house.gov/

4. Biologics Price Competition and Innovation Act, 2009

5. Public Health Service Act, 1944

6. FDA.

(n.d.). Orange Book Preface. Retrieved from

[FDA Website] (https://www.fda.gov/drugs/development-approval-process-drugs/orange-bookpreface).

7 Goodwin Law. (2020, September). The Purple Book and the Orange Book

When Do Patents and Exclusivities Expire? Retrieved from [Goodwin Law Blog] https://www.goodwinlaw.com/en/insights/blogs/2020/09/the-purple-book-and-theorange-book--when-do-paten.

8. Renu Lal, Pharm. D. (2014). The Purple Book [Electronic newsletter]. FDA/CDER

SBIA Chronicles, (November 18, 2014), 2. Retrieved from https://www.fda.gov/media/90150/download

9. The FDA Group. (n.d.). Abbreviated New Drug Applications (ANDA). Retrieved from

[FDA Group Website] https://www.thefdagroup.com/blog/abbreviated-new-drugapplications-anda.

10. What litigators can teach the patent office about pharmaceutical patents © 2022 S. Sean

Tu and Mark A. Lemley https://wustllawreview.org/wp-content/uploads/2022/08/whatlitigators-can-teach-the-patent-office-about-pharmaceutical-patents.pdf

11. Health Care Operations & Compliance, Professional Perspective - Hatch-Waxman

Overview https://www.bloomberglaw.com/external/document/X9P0AP7G000000/health-careoperations-compliance-professional-perspective-hatch

12 Drug Patents

How Pharmaceutical IP Incentivizes Innovation and Affects Pricing https://www.als.net/news/drug-patents/

13. Overview

of the Orange Book and the Off-Patent/Off-Exclusivity List https://www.wipo.int/edocs/mdocs/scp/en/scp_31/scp_31_h_orange.pdf

14. What is Hatch-Waman?, https://www.phrma.org/-/media/Project/PhRMA/PhRMA-

Org/PhRMA-Org/PDF/D-F/Fact-Sheet_What-is-Hatch-Waxman_June-2018.pdf

15. Laurie L. Hill, The Orange Book, Nature Reviews Drug Discovery 4, 621(2005)

16. Ashley M. Winkler; M. David Weingarten, Shana K. Cyr, Requirements, Benefits, and

Possible Consequences of Listing Patents in FDA’s Orange Book, July 3, 2018.

17. Xiaodong Feng, Hong-Guang Xie, Ashim Malhotra, Catherine F. Yang. "Biologics and

Biosimilars - Drug Discovery and Clinical Applications", CRC Press, 2022

18. Berry, I.R., & Martin, R.P. (Eds.). (2008) “The Pharmaceutical Regulatory Process

(2nd ed.)” CRC Press. https://doi.org/10.3109/9781420070439

19. Rägo L, Sillo H, Hoen E ‘t, Zweygarth M, “Regulatory Framework for Access to Safe,

Effective Quality Medicines. Antiviral Therapy.” 2014;19(3_suppl): 69-77. doi:10.3851/IMP2902

20. Korn DE, Lietzan E, Scott SW, “A new history and discussion of 180-day exclusivity.

Food Drug Law J”, 2009;64(2):335-90. PMID: 19999288.